Motif Bio board member resigns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
New York-based Motif Bio PLC said Robert Bertoldi will step down from its board, effective July 16.
Motif Bio is a clinical stage biopharmaceutical company that develops and sells pharmaceutical formulations in the U.S.
